Answers are grounded in this paper and cite their sources.
N6-methyladenosine (m6A) is the most prevalent internal modification of eukaryotic messenger RNA and has emerged as a major post-transcriptional regulator of cancer biology. In melanoma, dysregulated m6A deposition, removal, and recognition influence tumor-cell proliferation, phenotypic plasticity, invasion, metastatic competence, metabolic adaptation, and immune escape. Mechanistic studies have identified context-dependent functions of the METTL3–METTL14 methyltransferase complex, the demethylases FTO and ALKBH5, and reader proteins including YTHDF family members and IGF2BPs. These regulators also shape antitumor immunity by altering interferon signaling, antigen presentation, lactate metabolism, immune-cell infiltration, and sensitivity to immune-checkpoint blockade. In parallel, transcriptomic studies have generated m6A-related molecular subtypes and risk scores associated with prognosis and immunotherapy response, although their clinical utility remains unproven. Pharmacologic targeting of METTL3, FTO, ALKBH5, and m6A-dependent reader pathways provides a developing therapeutic framework, but selectivity, delivery, and cell-type specificity remain major challenges. This review synthesizes current evidence linking m6A regulation to melanoma progression, immune remodeling, biomarker development, and therapeutic intervention, while defining key evidence gaps that must be addressed before clinical translation can be achieved.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: